MAZEMaze Therapeutics, Inc.
What is the market doing?
No clear lean: nothing decisive, though heavily shorted (+11% of shares).
Rangebound, no clear trend. Price is −19% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How MAZE is trading
Maze Therapeutics, Inc. is +18% over the past year while the S&P 500 is +18%: 0.11 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −19%
vs 200-day average · a clear downtrend
- RSI (14)
- 69
RSI (14) · neutral
- Below its 52-week high
- 48%
Below its 52-week high
Details›
- Last close2026-10-09
- $27.11
- 1 monthS&P 500 +2.7%
- +9.2%
- 1 yearS&P 500 +18%
- +18%
- vs 50-day average$26.89
- +0.83%
- 52-week high
- $51.83
- 52-week low
- $22.40
- Annualised volatility
- 91%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$1.1M
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Biotechnology
The closest names by size in the same industry